Skip to content

Merck & Co. MRK Debt Repayments

Debt Repayments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$500M
Cytokinetics logo
CytokineticsCYTK
$2.74M+2.0%
Phibro Animal Health logo
Phibro Animal HealthPAHC
$65M-36.9%
United Therapeutics logo
United TherapeuticsUTHR
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$868K
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$16M+23.1%

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$317.37B+61.7%
Enterprise value$361.07B+60.4%
P/E35.5×+23.6×
P/S4.8×+1.7×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s debt repayments?
Merck & Co. (MRK) reported debt repayments of $1.14B in Q1 2026.
How has Merck & Co.'s debt repayments changed year-over-year?
Merck & Co.'s debt repayments decreased by 54.4% year-over-year, from $2.5B to $1.14B.
What is the long-term trend for Merck & Co.'s debt repayments?
Over 2 years (2022 to 2025), Merck & Co.'s debt repayments has grown at a 5.4% compound annual growth rate (CAGR), from $2.25B to $2.5B.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.